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Introduction
Varicella (chickenpox) is a highly contagious illness sustained 
by an α Herpes virus called varicella-zoster virus (VZV). 
Epidemiologically, this is an infection with an endemic-epidemic 
pattern that only affects humans and is air-transmitted as well as 
by direct contact with blisters. The causative agent is ubiquitous 
and mostly affects children; the maximum incidence is seen in 
the 0 to 14-y-age group.1
A particular characteristic of the causative agent is its ability 
to infect, during primary infection, skin nervous endings and 
become latent in nerve sensory ganglia.2 In detail, a replication 
phase in the penetration site is followed by a viremic phase when 
VZV spreads to skin and mucosae; the consequent replication 
leads to the typical rash and infection of nerve sensory ganglia 
in the epithelium. From here, the virus gains access to sensory 
ganglia where it remains latent. Reactivation of latent VZV 
virus, several years or even decades after experiencing primary 
infection, leads to a typical clinical manifestation called Herpes 
Zoster (HZ).3
Etiopathogenesis and Immunology
During primary infection, VZV migrates through sensory 
nerve fibers to corresponding dorsal root nerve ganglia. VZV 
becomes latent in the ganglia and remains there for the patient 
lifetime (latency). During the reactivation, nerve ganglia are the 
site of viral replication with ensuing neuropathic damage to nerve 
fibers; VZV follows the corresponding sensory ending until it 
reaches skin branches resulting into clinically evident HZ.4-7 
Therefore, HZ can be defined as an acute vesicular dermatitis, 
with typical unilateral distribution due to the reactivation of 
VZV acquired during the primary infection usually in pediatric 
age (chickenpox).8
With regard to immunology, natural VZV infection induces 
a long-term antibody-mediated and cell-mediated immunity 
(CMI) against the clinical form of the disease.9 However, natural 
acquired immunity does not prevent virus latentization nor the 
possible subsequent reactivation (HZ). The lack of specific anti-
VZV antibodies does not necessarily imply susceptibility, since 
the corresponding CMI can persist.10,11 Approximately 20% of 
subjects aged >50 y do not show a measurable specific CMI, 
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herpes Zoster (hZ) is a viral disease with painful neuro-dermatologic manifestations. Incidence increases with age. In 
Italy, the estimated incidence is 6.3 cases/1000 person/year; hospital admissions are less than 2%, 69% in patients aged 
over 65 years. The most frequent complication of hZ is Post-herpetic Neuralgia (PhN) characterized by metameric pain, 
allodynia, and hyperalgesia. In Italy 20.6% and 9.2% of hZ patients experience PhN after 3 and 6 months, respectively. 
available antiviral and analgesic treatments are relatively unsatisfactory in reducing pain and length of the disease. 
Prevention has recently become possible with the live attenuated vaccine Oka/Merck. clinical studies show a reduction of 
51% in the incidence of the disease, 61% of its burden and 67% of PhN in vaccinees. Protection seems to be long lasting and 
vaccine safety matches registration requirements. available evidence suggests that the costs for QaLY (less than € 20 000) 
and avoided cases is favorable. Due to the heavy burden of disease, it is time to offer this vaccination to elderly population.
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notwithstanding persistence of specific antibodies and a positive 
history of varicella.12,13
HZ is strictly related to a reduction in VZV-specific T 
lymphocytes; a Zoster episode reactivates specific T-cell 
response.14 Since varicella is an infectious disease that can 
virtually affect all subjects, especially in the pediatric age, most 
of the adult population has specific anti-VZV antibodies that are 
the expression of a previous contact with the infectious agent and 
has a latent form of VZV.15,16 As a consequence, most of the adult 
population is potentially susceptible to develop an episode of HZ 
in its lifetime.
Epidemiology
HZ is sporadic and occurs all over the year, completely 
un-related to varicella outbreaks. HZ cannot be transmitted. The 
only event that may occur is the transmission of the reactivated 
virus to subjects who had not been previously exposed to the virus; 
in this case, infected subjects contract varicella. All HZ-infected 
subjects constantly show a positive history of varicella.17
HZ is painful and unilateral, with a dermatomal distribution 
in the skin area corresponding to the nervous fiber that originates 
from a dorsal root ganglion. The most frequent localization is 
the thoracic segment (50–60%); other possible localizations 
are the trigeminal (cranial; 10–20% of HZ cases have an 
ocular localization: ophthalmic HZ), cervical, lumbar and 
sacral segments.18-21 After the acute phase, 20% of patients can 
experience complications, while recurrences are relatively rare 
(1–5%).22 The most fearful complication, being the expression of 
VZV neurotropism, is Post-Herpetic Neuralgia (PHN). PHN is 
a painful chronic condition, resistant to a number of treatments, 
affecting 10 to 20% of patients (some estimates report up to a 
third of patients) who have experienced an acute HZ episode.23-25
All authors agree that some factors are typically associated 
with HZ epidemiology, including age, cell-mediated immunity 
depression, intrauterine exposure to VZV and varicella occurring 
in early age (<18 months).26,27 Age and CMI depression are 
strictly related since increasing age leads to CMI decrease. Other 
authors maintain that also gender, seasonality, race, psychological 
distress, exposure to immunotoxic agents, mechanical traumas 
and genetic predisposition can play a crucial role in the 
development of HZ.
HZ incidence is similar all over the world and its trend is 
related to population age, with 2 to 3 cases/1000 person/years 
in the 20–50 y age group up to 5/1000 in the >60 age group, 
to 6–7/1000 in the 70–80 age group.28,29 It was estimated that 
over lifetime, at least 25% of the subjects will experience a HZ 
episode; two thirds of the cases in the world affect subjects 
aged >50 y. Considering the increase in the elderly and frail 
population, an increase in the number of cases is foreseen in the 
future. However, today over 1.7 million HZ cases are estimated 
to occur globally every year.29
Therefore, immunosenescence plays a crucial role; however, 
90% of HZ patients are not specifically immunocompromised. 
Besides age, HZ risk can be related to other co-morbidities 
(including diabetes, major depression, stressful events, 
immunosuppressive therapies) that induce reduced VZV-specific 
CMI response.30-32
In Europe, 95% of the adult population is estimated to be 
seropositive for anti-VZV antibodies and thus potentially 
susceptible to develop HZ in its lifetime.15
In Italy, over 22 million people aged >50 y live; 157 000 
new cases of HZ are estimated to occur every year. The annual 
incidence is 6.3/1000 person-years; 73% of cases affect adult 
subjects.33
A perspective study performed all over Italy in cooperation 
with General Practitioners showed that 20.6% and 9.2% of HZ 
patients aged >50 y had PHN at 3 and 6 months, respectively, 
notwithstanding an early antiviral treatment (started within 72 
h from skin rash onset). Also based on this study, the HZ/PHN 
burden is confirmed to increase with increasing age and HZ/
PHN considerably impact on the patient quality of life.34
Another study on hospital discharge records shows that over 
the period 1999–2005, 35 328 admissions due to HZ were 
recorded overall, of which 31 526 regular admissions and 3802 
in day-hospital setting. The annual average was 4503 regular 
admissions and 543 day-hospital admissions, i.e., about 14 
admissions/day. In the 1999–2005 period, 61.9% of admissions 
involved subjects aged ≥65 y and the average stay was 8 days.35 
These data, although taking into consideration only hospitalized 
cases recorded at national level, also confirm the epidemiological 
impact of HZ and associated complications.
Clinical Overview and Impact on Quality of Life
HZ is clinically characterized by vesicular rash and neuropathic 
pain with radicular distribution to which loss of sensitivity is 
often associated. The triad of HZ symptoms includes subjective 
symptoms, typical unilateral dermatomal rash, and regional 
painful lymphadenopathy.36
The clinical pattern is usually preceded by a prodromic phase 
with acute photophobia, pain, headache and general malaise. 
The acute phase, that appears suddenly, is characterized by 
rash with a dermatomal distribution, pain, unbearable pruritus 
and allodynia. The acute phase is usually followed by recovery; 
however, a number of possible complications, especially 
neurologic ones, may occur.6
Although HZ skin rash is temporarily disfiguring and quite 
annoying in a number of patients, the most important issue for 
patients is undoubtedly pain. HZ is basically a disease of the 
nervous system, being the most common infectious neurological 
manifestation.
HZ typical manifestations are limited to a specific body area 
but patient wellbeing is generally compromised.37
Around 20% of patients experience complications. In 
immunocompromised hosts, the main complication following 
HZ is pain persistence defined as Post-Herpetic Neuralgia 
(PHN). PHN is a fearful painful chronic condition, resistant to 
a number of treatments that affects 10–20% of patients (some 
estimates report up to a third of patients) who have experienced an 
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acute HZ episode. HZ is an extremely debilitating experience, for 
the affected subjects, with an impairment of physical, productive, 
and interpersonal abilities and with psychological effects in case 
of chronicization of the disease.38 HZ and PHN negatively affect 
the patient quality of life (QoL); besides suffering due to the 
typical symptoms of skin lesions and the associated pain, subjects 
can also have an impaired ability to perform daily activities or 
maintain social and family relationships. The whole spectrum of 
symptoms and related functional and social symptoms can cause 
a chronic alteration in the psychological status of the affected 
subject.39
The results from two trials, both performed in the United 
Kingdom, have been published very recently. The first study 
shows that HZ is an independent risk factor for vascular 
disease, in particular stroke, TIA and myocardial infarction in 
HZ subjects aged less than 40 y.40 The second study shows a 
relationship between HZ and stroke in the 6 months following 
Zoster appearance. The risk is particularly increased in patients 
with ophthalmic HZ.41
The objectives of the therapeutic treatments to be used in 
case of HZ include reducing the extent, the severity and duration 
of the infection, trying to prevent post-herpetic neuralgia and 
reduce any possible complications.42
The therapeutic approach includes symptomatic treatments, 
antibiotics to treat bacterial superinfections, antiviral therapy 
and nerve blocks.43 The guidelines highlight the importance 
to start antiviral therapy early, within 72 hours from symptom 
onset, in order to avoid loss of efficacy.28
Clinical trials show that 20–30% of patients treated within 
72 hours have developed post-herpetic neuralgia even so, and a 
Cochrane review demonstrated that use of antivirals does not 
prevent PHN.44
PHN is very difficult to treat, though several treatments are 
available. Briefly, corticosteroids reduce pain intensity, but do 
not prevent PHN and have several undesirable effects in elderly 
patients; analgesics can only reduce pain in the acute phase but 
a limited number of studies on PHN have been performed; 
antidepressants reduce PHN but are associated with a number 
of undesirable effects that impact patient QoL; opioids reduce 
PHN, but are associated with undesirable effects that make them 
difficult to manage especially in elderly patients; antiepileptics/
neuromodulators, i.e., gabapentin and pregabalin, reduce PHN, 
but do not improve patient Qol; topical analgesics lidocaine and 
capsaicin have limited efficacy.5,45-49
Prevention: Vaccines Currently Available
The evaluation of the epidemiological impact, the frequent 
and debilitating complications (especially PHN), the sub-optimal 
treatments of complications and the costs related to the diagnosis 
and clinical/therapeutic management of HZ patients (also 
including costs related to complications and hospitalizations, 
as well as societal costs) are the rationale and the reason for the 
search of an adequate preventive measure against this relevant 
disease. The target of this specific intervention is to reduce 
the frequency and severity of HZ and related complications by 
stimulating cell-mediated immunity.
Over the years, varicella vaccines, especially those with a high 
antigen level, have resulted able to elicit a significant increase in 
cell-mediated immune response in immunocompetent elderly 
patients.50-54
Zoster vaccine developed by Merck, and currently available 
on the market, has an antigen content higher than at least 19,400 
PFU (Plaque-Forming Units), i.e., at least 10 times higher than 
the antigen content in paediatric varicella vaccine.55
High-antigen Zoster vaccine was evaluated in a wide clinical 
trial called “Shingles Prevention Study” (SPS). SPS was a 
randomized, double-blind, placebo-controlled trial performed in 
the United States of America (USA) to establish if vaccination 
with a single dose of experimental live attenuated Oka/Merck 
strain vaccine can reduce the incidence and/or severity of HZ 
and PHN in men and women ≥60 y of age with a negative history 
of HZ but a positive history of varicella. Overall, 38 546 subjects 
(19 270 vaccinated and 19 276 treated with placebo) with a mean 
age of 69 y were enrolled in the study. Overall data on study 
population showed a reduction of 51.3% in the number of HZ 
cases, a reduction of 66.5% in PHN cases and a reduction of the 
overall burden of illness (BOI) of 61.1%.56
After the SPS, other trials on the efficacy and the effectiveness 
were performed.
The study called ZEST (Zoster Efficacy and Safety Trial) 
evaluated the efficacy of the vaccine against HZ in subjects aged 
from 50–59 y; efficacy was 70%.57
Within the SPS trial, other efficacy evaluations were performed 
in the short-term (STPS) as well as in the long-term (LTPS) 
prevention study. The short-term efficacy was 40%, 60%, and 
50% against HZ, PHN and HZ-induced pain, respectively.58
LTPS is currently ongoing; the estimated vaccine efficacy 
during the sub-study follow-up period was 21% for HZ 
incidence, 35% for PHN incidence, and 37.3% for the impact of 
HZ-induced pain.55
Also with regard to effectiveness, short-term and long-term trials 
are currently ongoing. With regard to short-term effectiveness, an 
efficacy study has been recently published based on data from 
the Kaiser Permanente Southern California (KPSC), aimed 
at assessing the risk of HZ in the general practice setting after 
vaccine administration. The results have shown an effectiveness of 
55% against HZ; the reduced incidence in vaccinees was reported 
in all age groups, also in subjects with chronic diseases. The study 
showed an effectiveness of 63% against ophthalmic HZ and 65% 
against hospitalizations coded as HZ.59
Another retrospective study on subjects enrolled in 
Medicare aged >60 y (average age 74 y ± 8 y) with immune-
mediated diseases (i.e., rheumatoid arthritis, psoriasis, psoriatic 
arthritis, ankylosing spondylitis, or ulcerative colitis) showed an 
effectiveness against HZ equal to 39%.60
With regard to the long-term effectiveness study, a pilot phase 
started in May 2012 at Kaiser Permanente Northern California 
(KPNC) and will continue until the end of 2014; two ad interim 
analyses will be available at the end of 2016 and end 2020 while 
the final report will be available by the end of 2024.
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With regard to safety and tolerability, Zoster vaccine was 
evaluated in large clinical trials that enrolled and vaccinated 
over 32 000 adults. Key trials were the Shingles Prevention Study 
(SPS) in subjects aged ≥60 y (SPS safety sub-study) and the 
Zoster Efficacy and Safety Trial (ZEST) in subjects aged 50–59 
y.56,57 Other clinical trials and post-marketing studies followed. 
In the SPS, the frequency of serious adverse events, systemic 
adverse events and hospitalizations was low; the vaccine used 
did not cause or induce HZ, not even in the weeks immediately 
following vaccination. In the ZEST study, the most frequent 
adverse reactions were injection-site adverse reactions (63.9% in 
the vaccinated group vs. 14.4% in the placebo group), most of 
which were of moderate intensity.
Taken together, clinical trials show that Zoster vaccine is 
generally well tolerated, the most commonly reported side effects 
(occurring in at least 1 in 10 individuals) being reactions at the 
injection site (redness, swelling, pain and itching) and headache 
(occurring in at least 1 of 100 and less than 1 of 10 individuals); 
the rate of zosteriform or varicella-like rashes not localized in the 
injection site within 42 days postvaccination was similar in the 
group of vaccinated subjects and in the placebo group and no cases 
of secondary tranmission of the vaccine virus were reported.61
The analysis of available data in the post-marketing period 
shows that the overall risk-benefit ratio for Zoster vaccine is 
favourable and supports claims on the vaccine safety; moreover, 
no age-related safety issues were reported.62-64
Indications of Use for Zoster Vaccine
In May 2006, Zoster vaccine received FDA marketing approval 
in the United States and then the early recommendations for its 
use were issued. In 2006, the vaccine was approved also by the 
European Medicines Agency (EMA) and it is currently on the 
market.55
According to the Summary of Product Characteristics 
(SPC),55 Zoster vaccine is indicated for the prevention of HZ 
and HZ-related Post-Herpetic Neuralgia (PHN). The vaccine is 
indicated for immunization of individuals 50 y of age or older 
and is effective and safe in subjects with a positive history of 
HZ.65 The vaccine is not indicated for the prevention of primary 
varicella infection (chickenpox) and should not be used in 
children and adolescents.
Contraindications include: 
•history of hypersensitivity to any of the excipients or trace 
residuals (e.g., Neomycin)
•primary and acquired immunodeficiency due to acute and 
chronic leukaemias; lymphoma; other conditions affecting 
the bone marrow or lymphatic system; immunosuppression 
due to HIV/AIDS; cellular immune deficiencies
•immunosuppressive therapy (including high-dose corticoste-
roids); however, it is not contraindicated for use in individuals 
who are receiving topical/inhaled corticosteroids or low-dose 
systemic corticosteroids or in patients who are receiving cor-
ticosteroids as replacement therapy
•active untreated tuberculosis
•pregnancy
Individuals should receive a single dose (0.65 ml) administered 
subcutaneously, preferably in the deltoid region; the need for a 
second dose is currently unknown. Contact with disinfectants 
should be avoided; it is recommended that the vaccine be 
administered immediately after reconstitution to minimize loss 
of potency. Reconstituted vaccine should be discarded if it is not 
used within 30 min.
With regard to interactions with other products, the vaccine 
can be administered concomitantly with inactivated influenza 
vaccine, as separate injections and at different body sites.
Zoster vaccine and 23-valent pneumococcal polysaccharide 
vaccine should not be given concomitantly because 
co-administration in clinical trials resulted in reduced 
immunogenicity of Zoster vaccine. No data are currently 
available regarding concomitant use with other vaccines; 
co-administration of Zoster vaccine and anti-viral medications 
known to be effective against VZV has not been evaluated.
EUnetHTA (European Network of Agencies or national 
institutions dealing with Health Technology Assessment, HTA) 
has recently acknowledged the clinical efficacy/effectiveness of 
Zoster vaccine in the population aged >50 y also highlighting a 
protection duration up to 10 years.66
Globally, immunization with this vaccine is recommended, 
with or without public funding, in a number of countries:
1) in USA and Canada, it has been recommended in patients 
aged 60 y or older, since 2006 and 2010, respectively;
2) in Europe, vaccination is recommended and/or reimbursed:
 •in Austria since 2007 (cohorts aged over 50 y of age)
 •in United Kingdom (UK) (cohorts aged 70 y and catch up 
in cohorts aged 71 to 79 y) since 2010
 •Germany/Saxony (cohorts aged over 50 y of age) since 2010
 •Sweden (cohorts aged over 50 y of age) since 2010
 •Greece (cohorts aged over 60 y at high risk) since 2011
 •France (cohorts aged 65 to 74 y, catch up in cohorts aged 75 
to 79 y) since 2013
A recent cost-efficacy study measured the impact of 
vaccination in subjects aged ≥65 y and in the 70–79 y age group, 
concluding that the vaccination is cost-effective.67
In Italy, an economic evaluation study has been performed; 
it showed that the vaccination program against HZ and PHN is 
cost-effective from both the societal and third-payer perspectives 
in subjects aged 60–79 y.68
Expert Recommendations
Herpes Zoster is a relevant public health issue. Over 95% 
of the adult population is seropositive to specific anti-VZV 
antibodies and therefore is potentially at risk of developing HZ 
in its lifetime.
The risk to develop HZ and PHN increases with age and 25% 
of adults will develop HZ in their lifetime. The risk to develop 
HZ seems to be related to a decline in cell-mediated immunity 
(CMI) against VZV virus. HZ clinical pattern and associated 
acute and chronic pain are debilitating and have a considerable 
impact on patient quality of life. Treatment options of HZ and 
PHN are often sub-optimal. Finally, costs for the diagnosis 
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and clinical and therapeutical management of acute HZ, for 
hospitalizations, complications and societal costs are high. The 
epidemiological data available in Italy are scientifically robust and 
consistent with similar data reported in Europe and in the United 
States. HZ-related suffering is also aggravated by a considerable 
economic burden: pharmacoeconomic studies estimate an annual 
cost ranging from 41 to 99 billion Euro in Europe and a cost of 
41 million Euro in Italy.
All above mentioned reasons represent the rationale for the 
prevention of this important infectious disease; the possibility to 
prevent this disease by means of vaccination is a very interesting 
perspective.
Zoster vaccine was conceived in order to increase VZV-specific 
immunity just like a natural case of HZ can increase immunity. 
Zoster vaccine has a booster effect in immunized subjects by 
eliciting a significant increase in CMI; this CMI increase can 
only be obtained by a high-potency vaccine.
The vaccine that is currently available has good 
immunogenicity, clinical efficacy, effectiveness and safety 
profiles: briefly, at least half of the cases would be avoided by 
vaccination with a considerable impact also in terms of reduction 
of disease severity and complications, mainly post-herpetic 
neuralgia. Moreover, pharmacoeconomic studies provide 
evidence of the cost-effectiveness profile of the vaccination that 
is already recommended, with or without public funding, in a 
number of countries all over the world.
Based on scientific data, the Public Health best strategy would 
be to offer the vaccine to the population aged 60–70 y. Aging 
is the main risk factor for HZ and an age-based strategy would 
allow to reach also subjects aged over 50 y with chronic diseases, 
in which the onset of HZ could cause serious complications.
The way the vaccine can be offered to the target population 
should include a common strategy to progressively ensure an 
equitable offer compatible with the available resources, being 
convinced that vaccination is convenient both in terms of quality 
of life and health economy.
This immunization shows that vaccinations in adults and in 
elderly people should not be considered separately from those 
for children and adolescents, but as a fundamental part of a 
preventive strategy against infectious diseases that should involve 
all age groups. There is a need for vaccination continuity in all 
age groups, considering that the increase of coverage rates in 
adults and elderly subjects necessarily requires an increase in the 
demand by the community, an optimization of organizational 
issues as well as a greater awareness by Healthcare Professionals.
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